Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Revised Alexza Deal Suggests Updated Strategy For Symphony Capital

Executive Summary

With the dissolution of Symphony Allegro and the return of the joint venture's three clinical programs to Alexza, Symphony Capital should have its exit from the $50 million investment it made in the biotech and its Staccato aerosol inhalation technology in 2006
Advertisement

Related Content

Lexicon Buys Back GI Drugs from Symphony Capital, But Plenty of Risk Remains
New Frontiers in Pharma R&D Investment
New Frontiers in Pharma R&D Investment
Troubled Biotechs: Alexza, Synvista, Alseres, Bionovo
Symphony's Project Financing Model Adapts
Symphony's Project Financing Model Adapts
Exelixis, GSK Deal Comes To A ‘Natural, Positive End’
Alexza’s Acute-Panic Drug Fails In Phase IIa
Alexza Moves Lead Candidate AZ-004 Into Phase III For Agitation In Schizophrenia

Topics

Advertisement
UsernamePublicRestriction

Register

PS051247

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel